Genetic Viral and Host Adaptations to Breach Species Barriers of HCV
Genetic Viral and Host Adaptations to Breach Species Barriers of HCV
批准号:
10202407
负责人:
Alexander Ploss
金额:
$47.48万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-01 至 2023-06-30
关键词:
AftercareAlcohol consumptionAnimal ModelAntiviral AgentsCellsCenters for Disease Control and Prevention (U.S.)CercopithecidaeCessation of lifeChronic Hepatitis CCirrhosisCommunicable DiseasesComplementCyclophilin ADataDevelopmentDiabetes MellitusDistantDrug usageFibrosisGermanyHCV Animal ModelsHIVHealth Services AccessibilityHepatitis CHepatitis C TherapyHepatitis C TransmissionHepatitis C virusHepatitis C-Like VirusesHepatocyteHumanImaging TechniquesImmune responseIn VitroIndividualInfectionIntegration Host FactorsKnock-in MouseLeadLiver Stem CellLiver diseasesMalignant neoplasm of liverMusNatural ImmunityObesityOrthologous GenePan GenusPatientsPeptidylprolyl IsomerasePongidaePrimary carcinoma of the liver cellsPrimatesPublic HealthPublishingRNARNA replicationReportingResearchRodentSeminalShapesTestingTissuesTransgenic MiceTreatment CostTropismVaccinesViralViral PathogenesisVirusVirus ReplicationWorkadvanced diseasecancer riskchronic infectionco-infectioncomorbidityhigh riskimprovedin vivoinsightliver transplantationloss of functionnovelpathogenpreventreceptorresponsesingle-cell RNA sequencingstem cell biologystem cellstranscriptomicstransmission processvaccine candidatevaccine evaluationvirus genetics
中文摘要
项目摘要
丙型肝炎病毒(HCV)是一种重要的传染病,在约71
全球百万人。CDC估计,美国每年约有30,000例新的HCV病例,
每年约有20,000人死亡,使HCV比其他60种传染病的总和更致命,包括
艾滋病。然而,导致慢性HCV感染后出现终末期肝病的潜在机制
我们对此知之甚少。虽然慢性丙型肝炎现在可以有效地治疗直接作用的抗病毒药物
由于治疗费用极高,预防传播的疫苗仍然是高度优先事项
(12周课程80,000美元以上)。此外,一旦感染,个人仍然处于肝病的高风险之中
甚至是治疗后。建议的工作将以我们的大量研究结果为基础,有系统地继续进行。
分析造成HCV种间传播障碍的机制。
目的1:确定不同物种中支持HCV复制的已知宿主因子的机制。
HCV依赖于多种宿主因子在肝细胞中建立复制。我们的初步数据显示
对于所有测试的类人猿,肽基脯氨酰异构酶A(也称为亲环素A(CypA))的直系同源物支持
HCV RNA复制。然而,远亲物种的CypA,如新大陆和旧大陆的猴子,
老鼠的效率要低得多。我们的目标是机械地定义这个主机和其他主机的潜在不兼容性
这些因子与HCV复制机制的病毒编码成分有关。
目的2:研究灵长类动物HCV感染及其免疫应答网络
和啮齿动物种类。我们将研究丙型肝炎病毒是否可以感染和复制在一组新的干细胞衍生的细胞,
肝细胞样细胞来自一系列进化上不同的物种,包括大猿,选择新的和旧的
世界上的猴子和啮齿动物。在第二步中,我们将使用高通量单细胞RNA测序来获得
与HCV复制相关的物种特异性转录组反应网络。
目的3:研究CD 302和Cr 1 L在体内抑制HCV感染的作用。人为进入因素
先天免疫功能减弱的转基因小鼠只支持低水平的病毒复制,这表明小鼠
限制因子可以抑制病毒在体内的复制。我们的初步数据表明,小鼠CD 302和
补体成分(3b/4 b)受体1样(Cr 1 L)在体外限制HCV复制。在这里,我们将评估如果损失-
在我们的HCV进入因子敲入小鼠中,mCD 302和mCr 1 L的功能缺失增强了HCV感染。
这项工作将为研究HCV的种属嗜性提供新的思路。Ploss实验室已经做出了许多
开创性的贡献,该领域,并将在这一重要工作的帮助下,我们的长期合作者博士。
Schwartz(Weill Cornell)、Shalek(MIT)和Pietschmann(Twincore,德国)。我们的工作将推动这一领域
通过在开发适合研究HCV的小动物模型方面取得进展,
感染和免疫反应,这是改善治疗和开发疫苗的必要前提。
英文摘要
Project summary
Hepatitis C virus (HCV) is an important and underreported infectious disease, causing chronic infection in ~71
million people worldwide. The CDC estimates there are ~30,000 new cases of HCV every year in the US and
about 20,000 deaths annually, making HCV more deadly than 60 other infectious diseases combined, including
HIV. However, the underlying mechanisms that lead to chronic HCV infection followed by end-stage liver disease
are poorly understood. Although chronic hepatitis C can now be effectively treated with direct-acting antivirals
(DAAs), a vaccine to prevent transmission remains a high priority due to extremely high treatment costs
($80,000+ for a 12-week course). Furthermore, once infected, individuals remain at high risk for liver disease
even post-treatment. The proposed work will build on our substantial research findings to continue systematically
analyzing the mechanisms that create barriers to interspecies HCV transmission.
Aim 1: Define mechanisms of known host factors from diverse species that support HCV replication.
HCV relies on a variety of host factors to establish replication in hepatocytes. Our preliminary data demonstrate
that for all great apes tested, orthologs of peptidylprolyl isomerase A, also known as cyclophilin A (CypA), support
HCV RNA replication. However, CypA of distantly related species, such as New and Old World monkeys and
mice, is far less efficient. We aim to define mechanistically the underlying incompatibility of this and other host
factors with the virally encoded components of the HCV replication machinery.
Aim 2: Characterize HCV infection and immune response networks following infection across primate
and rodent species. We will study whether HCV can infect and replicate in a novel set of stem cell-derived
hepatocyte-like cells from a range of evolutionarily diverse species, including great apes, selected New and Old
World monkeys and rodents. In a second step, we will use high-throughput single-cell RNA sequencing to derive
species-specific transcriptomic response networks associated with HCV replication.
Aim 3: Characterize the impact of CD302 and Cr1L on restricting HCV infection in vivo. Human entry factor
transgenic mice with blunted innate immunity only support low-level viral replication, suggesting murine
restriction factors may suppress viral replication in vivo. Our preliminary data indicate mouse CD302 and
complement component (3b/4b) receptor 1-like (Cr1L) limit HCV replication in vitro. Here, we will assess if loss-
of-function of mCD302 and mCr1L augments HCV infection in our HCV entry factor knock-in mice.
The proposed work will provide new insights into the species tropism of HCV. The Ploss lab has made many
seminal contributions to the field and will be aided in this important work by our long-standing collaborators Drs.
Schwartz (Weill Cornell), Shalek (MIT) and Pietschmann (Twincore, Germany). Our work will advance the field
of HCV research by making progress in the development of small animal models suitable for studying HCV
infection and immune responses, a necessary precursor to improving treatment and developing vaccines.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of hepatitis B virus cccDNA formation
-
批准号:10393606
-
项目类别:
-
资助金额:$55.41万
-
财政年份:2020
-
负责人:Alexander Ploss
-
依托单位:
Mechanisms of hepatitis B virus cccDNA formation
-
批准号:10165502
-
项目类别:
-
资助金额:$55.41万
-
财政年份:2020
-
负责人:Alexander Ploss
-
依托单位:
Mechanisms of hepatitis B virus cccDNA formation
-
批准号:10610864
-
项目类别:
-
资助金额:$55.41万
-
财政年份:2020
-
负责人:Alexander Ploss
-
依托单位:
Mechanisms of hepatitis B virus cccDNA formation
-
批准号:10032771
-
项目类别:
-
资助金额:$55.41万
-
财政年份:2020
-
负责人:Alexander Ploss
-
依托单位:
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection
-
批准号:10371657
-
项目类别:
-
资助金额:$76.43万
-
财政年份:2018
-
负责人:Alexander Ploss
-
依托单位:
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection
-
批准号:9981621
-
项目类别:
-
资助金额:$3.05万
-
财政年份:2018
-
负责人:Alexander Ploss
-
依托单位:
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection
-
批准号:10228671
-
项目类别:
-
资助金额:$78.32万
-
财政年份:2018
-
负责人:Alexander Ploss
-
依托单位:
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection
-
批准号:9789829
-
项目类别:
-
资助金额:$78.35万
-
财政年份:2018
-
负责人:Alexander Ploss
-
依托单位:
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection
-
批准号:10471797
-
项目类别:
-
资助金额:$78.32万
-
财政年份:2018
-
负责人:Alexander Ploss
-
依托单位:
Impact of species-specific host responses on restriction of hepatotropic viruses
-
批准号:9104080
-
项目类别:
-
资助金额:$24.86万
-
财政年份:2015
-
负责人:Alexander Ploss
-
依托单位:
Impact of species-specific host responses on restriction of hepatotropic viruses
-
批准号:8871022
-
项目类别:
-
资助金额:$22.27万
-
财政年份:2015
-
负责人:Alexander Ploss
-
依托单位:
Transmitted/Founder HCV clones as targets for treatment and eradication.
-
批准号:8732602
-
项目类别:
-
资助金额:$20.45万
-
财政年份:2013
-
负责人:Alexander Ploss
-
依托单位:
Genetic viral and host adaptations to breach species barriers of HCV
-
批准号:8562610
-
项目类别:
-
资助金额:$37.84万
-
财政年份:2013
-
负责人:Alexander Ploss
-
依托单位:
Transmitted/Founder HCV clones as targets for treatment and eradication.
-
批准号:8511202
-
项目类别:
-
资助金额:$24.73万
-
财政年份:2013
-
负责人:Alexander Ploss
-
依托单位:
Genetic Viral and Host Adaptations to Breach Species Barriers of HCV
-
批准号:10428523
-
项目类别:
-
资助金额:$46.63万
-
财政年份:2013
-
负责人:Alexander Ploss
-
依托单位:
Genetic viral and host adaptations to breach species barriers of HCV
-
批准号:9297200
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2013
-
负责人:Alexander Ploss
-
依托单位:
Genetic viral and host adaptations to breach species barriers of HCV
-
批准号:8688144
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2013
-
负责人:Alexander Ploss
-
依托单位:
海外基金